Skip to content

Monitoring of Mobility of Parkinson's Patients for Therapeutic Purposes - Clinical Trial

Monitoring of Mobility of Parkinson's Patients for Therapeutic Purposes - Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04176302
Acronym
MoMoPa-EC
Enrollment
173
Registered
2019-11-25
Start date
2019-11-26
Completion date
2023-06-21
Last updated
2025-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

Motor fluctuation, Parkinson, Accelerometer, Parkinson diary

Brief summary

When Parkinson Disease is mild, it responds well to treatment with drugs (L-Dopa and dopamine antagonists). However, as the disease progresses, the effect of the drugs diminishes and lasts for a shorter time (wearing-off), which require physicians to progressively increase and/or break up the dosage of dopamine drugs, to control symptoms over the course of the entire day. Despite this, most patients present motor fluctuations after 10 years. These fluctuations consist of changes between what are known as Off periods, when the medication does not produce an effect and mobility is hindered, and On periods when patients can move smoothly, with the medication producing its best effect. The timeline of these motor fluctuations over the course of the day and also on different days is very valuable to precisely adjust the medication. Nevertheless, neurologists do not currently have detailed information on the timeline of the symptoms of their patients, which means that they have serious difficulties to obtain good results with the adjustment of medication. Currently, the neurologist's information on the time progression of the motor fluctuations is drawn from what the patient indicates in the office visit, or in the best case, from diaries that the patient fills out at home, periodically (e.g. every hour) noting the motor state (On or Off). Although the latter method is still the gold standard in research and in care, it has serious limitations, because patients often forget to record the information (especially when they are in Off), many do not recognize their motor states well, and few can maintain adherence to such a laborious system for more than a few days. The Parkinson Holter (STAT-ON ®) is a wearable device, which objectively measures and records the motor fluctuations of the patients. It does not require intervention by the patient, and can, therefore, be used in daily life, long term if necessary. However, the concept that detailed knowledge of motor fluctuations of patients will lead to better control of the disease, thanks to optimisation of the therapeutic regimen, is still a hypothesis. To demonstrate or refute this hypothesis, we are now conducting a clinical trial, with this medical device, to study the clinical effectiveness in patients with moderate Parkinson's disease and motor fluctuations. This trial will show whether using the Parkinson Holter is better than the clinical interview used in traditional clinical practice (primary objective), and whether it is not inferior to the On-Off diary recorded by the patients at home (exploratory objective)

Interventions

DEVICEParkinson Holter

The neurologists will receive the wearable report (for medication adjustment, if any as per physician's criteria/judgement)

DIAGNOSTIC_TESTMotor fluctuations diary

The neurologists will receive the patient's diary report (for medication adjustment, if any as per physician's criteria/judgement).

OTHERTraditional clinical practice

The neurologists will receive the patient & caregiver report at the time of the visit (for medication adjustment, if any as per physician's criteria/judgement).

Sponsors

Instituto de Salud Carlos III
CollaboratorOTHER_GOV
European Regional Development Fund
CollaboratorOTHER
Consorci Sanitari de l'Alt Penedès i Garraf
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Ideopathic Parkinson's Disease * Disease in the moderate-severe phase (Hoehn & Yahr ≥ 2 en Off) * Motor fluctuations (with at least 2h/day in Off) * Agree to participate voluntarily and will sign a written consent form

Exclusion criteria

* Incapable of walking independently or H&Y=5 * Participating in another clinical trial * Patients with acute intercurrent disease * Psychiatric or cognitive disorders that prevent collaboration (MMSE \<24)

Design outcomes

Primary

MeasureTime frameDescription
Daily time in Off7 daysChanges from baseline to last visit in daily hours in Off

Secondary

MeasureTime frameDescription
Patient's adherence to the MF measurement system7 daysTotal hour/days with information registered.
Number of therapeutic changes.6 monthsNumber of therapeutic changes done to improve symptoms.
Motor complications6 monthsChanges from baseline to last visit in motor complications, assessed by means of Unified Parkinson's Disease Rating Scale - part IV
Daily time in On7 daysChanges from baseline to last visit in daily hours in On
Number of clinical contacts6 monthsNumber of patient visits and telephone controls to adjust medication
Reported quality of life1 monthChanges from baseline to last visit in quality of life, assessed by menas of Parkinson's Disease Questionnaire-39
Activities of Daily Living6 monthsChanges from baseline to last visit in dependence for Activities of Daily Living assessed by means of Unified Parkinson's Disease Rating Scale - part II
User satisfaction: Quebec User Evaluation of Satisfaction with assistive Technology7 daysPhysician and patient satisfaction with the Parkinson Holter will be assessed by means of the Quebec User Evaluation of Satisfaction with assistive Technology (QUEST)
System usability: System Usability Scale7 daysUsability of the system will be assessed by System Usability Scale (SUS)
Change of presence and severity of freezing of gait episodes7 daysChanges from baseline to last visit in the number and severity of freezing of gait episodes, assessed by means of Freezing of Gait Questionnaire

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026